COMMUNIQUÉS West-GlobeNewswire

Santhera Appoints Orlando Oliveira as Chief Executive Officer
23/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of [...]
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
23/04/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
23/04/2026
Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three [...]
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
23/04/2026
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN [...]
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
23/04/2026
Croissance du chiffre d’affaires total de 22,6 % à taux de change constant 1 , ou 17,0 % en données publiées, portée par les trois aires thérapeutiques, avec une accélération de la dynamique du portefeuille hors [...]
Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement
23/04/2026
CHICAGO, 23 avr. 2026 (GLOBE NEWSWIRE) -- L’une des questions les plus fondamentales de la biologie est de comprendre comment un seul œuf fécondé produit la diversité des types cellulaires constituant le corps — des [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
23/04/2026
Group sales were +6% at constant exchange rates (CER) 1 , -5% when reported in CHF and +9% in USD 2 , in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals [...]
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
23/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing [...]
New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources
23/04/2026
COPENHAGEN, Denmark, April 23, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation Challenge Programme supports development of new knowledge to help tackle major societal challenges within human and planetary health. [...]
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
23/04/2026
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company [...]
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
22/04/2026
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The [...]
PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels
22/04/2026
Collaboration expands access to affordable pet medications for rural communities nationwide DELRAY BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of [...]
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
22/04/2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
22/04/2026
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the [...]
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
22/04/2026
CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
Altimmune Announces Proposed Underwritten Public Offering of Securities
22/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
22/04/2026
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU who remain [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
22/04/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée Approbation pour les [...]
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage
22/04/2026
Significant lowering of systolic blood pressure of 9mmHg on top of background treatment maintained with GMRx2 over an average follow-up of 3 years Safety findings similar to previous studies of GMRx2 London, UK, Boston [...]

Pages